Oncovita is developing oncolytic therapies using its proprietary Measovir™ platform, which employs a modified measles virus to selectively target and destroy cancer cells while activating the immune system. This approach addresses the urgent need for effective treatments against various cancers, particularly in patients with limited therapeutic options.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer remains a leading cause of death, with a pressing need for more effective and safer treatments, especially for patients with limited options or those who do not respond well to conventional therapies. Traditional cancer treatments can have significant side effects and may not be effective for all types of cancer or in all patients.
Solution
Oncovita is developing oncolytic immunotherapies based on its Measovir™ platform, which utilizes a modified measles virus to selectively target and destroy cancer cells while simultaneously stimulating the patient's immune system to fight the disease. The Measovir™ platform leverages the measles virus's natural affinity for cancer cells, which often overexpress the CD46 receptor, allowing for targeted delivery and minimizing harm to healthy tissues. The modified virus induces immunogenic cell death, releasing tumor-associated antigens that activate the immune system and promote long-term anti-cancer immunity. This approach aims to provide a safe and effective treatment option for a variety of cancers, including hematological cancers and solid tumors.
Target Audience
The primary target audience includes patients with hematological cancers and solid tumors who have limited treatment options or who have not responded well to conventional therapies, as well as oncologists and researchers seeking novel and effective cancer treatments.
Features
- Proprietary Measovir™ platform based on a modified measles Schwarz virus.
- Selective targeting of cancer cells via the CD46 receptor, which is overexpressed in many cancer types.
- Induction of immunogenic cell death, releasing tumor-associated antigens to stimulate the immune system.
- Potential for combination with other immunotherapies to enhance anti-cancer responses.
- Demonstrated safety profile based on the well-established safety of measles vaccines.
- Utilizes a clonal reverse genetics system for generating recombinant viruses.